Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal Adenocarcinoma

被引:1620
作者
Provenzano, Paolo P. [1 ]
Cuevas, Carlos [4 ]
Chang, Amy E. [1 ]
Goel, Vikas K. [1 ]
Von Hoff, Daniel D. [5 ]
Hingorani, Sunil R. [1 ,2 ,3 ]
机构
[1] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98109 USA
[2] Fred Hutchinson Canc Res Ctr, Publ Hlth Sci Div, Seattle, WA 98109 USA
[3] Univ Washington, Sch Med, Div Med Oncol, Seattle, WA 98195 USA
[4] Univ Washington, Dept Radiol, Seattle, WA 98195 USA
[5] Translat Genom Res Inst, Clin Translat Res Div, Scottsdale, AZ 85259 USA
关键词
INTERSTITIAL FLUID PRESSURE; BLOOD-PRESSURE; CANCER; GEMCITABINE; HYALURONAN; TRANSPORT; TUMORS; HYPERTENSION; DELIVERY; TRIAL;
D O I
10.1016/j.ccr.2012.01.007
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Pancreatic ductal adenocarcinomas (PDAs) are characterized by a robust fibroinflammatory response. We show here that this desmoplastic reaction generates inordinately high interstitial fluid pressures (IFPs), exceeding those previously measured or theorized for solid tumors, and induces vascular collapse, while presenting substantial barriers to perfusion, diffusion, and convection of small molecule therapeutics. We identify hyaluronan, or hyaluronic acid (HA), as the primary matrix determinant of these barriers and show that systemic administration of an enzymatic agent can ablate stromal HA from autochthonous murine PDA, normalize IFP, and re-expand the microvasculature. In combination with the standard chemotherapeutic, gemcitabine, the treatment permanently remodels the tumor microenvironment and consistently achieves objective tumor responses, resulting in a near doubling of overall survival.
引用
收藏
页码:418 / 429
页数:12
相关论文
共 56 条
  • [1] Allison DC, 1998, J SURG ONCOL, V67, P151, DOI 10.1002/(SICI)1096-9098(199803)67:3<151::AID-JSO2>3.3.CO
  • [2] 2-4
  • [3] [Anonymous], 1984, Handbook of Physiology. The Cardiovascular System Microcirculation
  • [4] BALAZS EA, 1989, CIBA F SYMP, V143, P265
  • [5] Putting tumours in context
    Bissell, MJ
    Radisky, D
    [J]. NATURE REVIEWS CANCER, 2001, 1 (01) : 46 - 54
  • [6] BOUCHER Y, 1991, CANCER RES, V51, P6691
  • [7] BOUCHER Y, 1992, CANCER RES, V52, P5110
  • [8] Targeting tumor stroma and exploiting mature tumor vasculature to improve anti-cancer drug delivery
    Bouzin, Caroline
    Feron, Olivier
    [J]. DRUG RESISTANCE UPDATES, 2007, 10 (03) : 109 - 120
  • [9] Brekken C, 2000, ANTICANCER RES, V20, P3513
  • [10] Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: A randomized trial
    Burris, HA
    Moore, MJ
    Andersen, J
    Green, MR
    Rothenberg, ML
    Madiano, MR
    Cripps, MC
    Portenoy, RK
    Storniolo, AM
    Tarassoff, P
    Nelson, R
    Dorr, FA
    Stephens, CD
    VanHoff, DD
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (06) : 2403 - 2413